May 14, 2026
Shionogi pill prevents COVID-19 in household exposure study
The results mark the first late-stage success for an oral antiviral used to prevent COVID-19 after exposure.
Read More
May 13, 2026
Trials demonstrate Paxlovid’s evolving role against COVID-19
Paxlovid’s role in treating COVID-19 is not ending — it is evolving, according to the results of two national trials published in The New England Journal of Medicine.Although the trials — one conducted in the United Kingdom (PANORAMIC) and the other in Canada (CanTreatCOVID) — determined that Paxlovid (nirmatrelvir-ritonavir, Pfizer) does not reduce the incidence of hospitalization or death among vaccinated high-risk patients with SARS-CoV-2 compared with usual care, the combination medication sped up recovery in a meaningful way, experts noted.Nirmatrelvir-ritonavir is an antiviral regimen
Read More
May 13, 2026
New England Journal of Medicine Publishes Shionogi Study Demonstrating Ensitrelvir Prevents COVID-19 Following Exposure
Shionogi & Co., Ltd. (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, PhD; hereinafter “Shionogi”) announced that results from its global, double-blind, randomized, placebo-controlled Phase 3 study, SCORPIO-PEP, were published in the New England Journal of Medicine. A five-day course of ensitrelvir significantly reduced the risk of symptomatic COVID-19 by 67% in individuals following exposure to an infected individual through Day 10 compare
Read More
